Historical valuation data is not available at this time.
Mologen AG was a German biopharmaceutical company focused on the development of immunotherapies for cancer and infectious diseases. The company's core technology platforms included DNA-based immunomodulators and cell-based therapies. Mologen's lead product candidate was lefitolimod, a TLR9 agonist investigated for oncology indications. The company faced significant challenges in clinical development and funding, ultimately filing for insolvency in 2019. Its assets were acquired by Telix Pharmaceuticals in 2020.
Mologen's primary innovation was its MIDGE (minimalistic immunogenically defined gene expression) platform for DNA-based therapeutics. The company held patents related to this technology.
Mologen AG represents a case study in biotech development challenges. The company's innovative platform was not sufficient to overcome clinical and financial hurdles. With the company's assets now acquired by Telix Pharmaceuticals, there is no current investment case for Mologen AG. The historical example underscores the high risk nature of developmental stage biopharmaceutical companies.
Mologen AG insolvency filings, Telix Pharmaceuticals acquisition announcement, company historical SEC filings